Omeros closes $126M OMIDRIA sale to Rayner; deal valued >$1B including royalties

OMEROS CORP

Received ~$126M cash at closing; retains accounts receivable.
Eligible for $200M milestone if separate OMIDRIA payment secured for 4 consecutive years before 2025.
US royalty: 50% of net sales until milestone/2025, then 30% through patent life (2032).
Ex-US royalty: 15% of net sales on country-by-country basis.
Transaction removes OMIDRIA revenue and costs from continuing ops; pro forma shows ongoing R&D and SG&A.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.